Loss of the leukemia inhibitory factor receptor (LIFR) confers HCC proliferation and sorafenib-induced ferroptosis resistance by increasing the expression of the iron-sequestering cytokine LCN2 37. Here, LIFR is linked to hepatocellular carcinoma.